[
  {
    "ts": null,
    "headline": "4 Outpatient Home Health Stocks Worth Watching Amid Shifting Trends",
    "summary": "An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, DVA, ADUS and PNTG are well-poised to gain.",
    "url": "https://finnhub.io/api/news?id=2319c64c4bf2d024e26a843fb0af99448d731b3103a0bcfa3c44d8eae0b8cf8d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758733860,
      "headline": "4 Outpatient Home Health Stocks Worth Watching Amid Shifting Trends",
      "id": 136866400,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, DVA, ADUS and PNTG are well-poised to gain.",
      "url": "https://finnhub.io/api/news?id=2319c64c4bf2d024e26a843fb0af99448d731b3103a0bcfa3c44d8eae0b8cf8d"
    }
  },
  {
    "ts": null,
    "headline": "Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant’s Shield™ Blood-based Screening Test in the United States",
    "summary": "PALO ALTO, Calif. & SECAUCUS, N.J., September 24, 2025--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a broad strategic collaboration to make Guardant’s Shield™ blood-based screening test available to physicians and patients served by Quest in the United States.",
    "url": "https://finnhub.io/api/news?id=c82a81d20b2078c7065e80a0a50364aff8bf0829e6b34772226fee7c60cf9617",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758715500,
      "headline": "Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant’s Shield™ Blood-based Screening Test in the United States",
      "id": 136862167,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "PALO ALTO, Calif. & SECAUCUS, N.J., September 24, 2025--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a broad strategic collaboration to make Guardant’s Shield™ blood-based screening test available to physicians and patients served by Quest in the United States.",
      "url": "https://finnhub.io/api/news?id=c82a81d20b2078c7065e80a0a50364aff8bf0829e6b34772226fee7c60cf9617"
    }
  },
  {
    "ts": null,
    "headline": "Quest partners with Epic to boost laboratory testing services in US",
    "summary": "Epic will provide its diagnostic enterprise suite for laboratories to support Quest’s multi-year Project Nova programme.",
    "url": "https://finnhub.io/api/news?id=83a2fdef9ada83f482bb31fc43da780d015c69afdba934da580c33b7ce179836",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758705985,
      "headline": "Quest partners with Epic to boost laboratory testing services in US",
      "id": 136862168,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Epic will provide its diagnostic enterprise suite for laboratories to support Quest’s multi-year Project Nova programme.",
      "url": "https://finnhub.io/api/news?id=83a2fdef9ada83f482bb31fc43da780d015c69afdba934da580c33b7ce179836"
    }
  }
]